{
    "clinical_study": {
        "@rank": "11552", 
        "brief_summary": {
            "textblock": "The purpose of this study is to find a noninvasive test to help physicians diagnose detrusor\n      overactivity (DO), to use this urine test to help diagnose bladder problems, determine if\n      treatments are working, and determine if patients are good candidates for interventions like\n      sacral neuromodulation/Interstim Therapy."
        }, 
        "brief_title": "UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation", 
        "condition": "Detrusor Overactivity", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  for controls: age greater than or equal to 18; female gender, ability to provide\n             informed consent and complete study requirements; subject has to be without urinary\n             symptoms\n\n          -  for cases: age greater than or equal to 18; female gender; ability to provide\n             informed consent and complete study requirements; the subject should have symptoms of\n             detrusor overactivity, including urinary frequency, urgency, or urge incontinence,\n             for greater than or equal to 3 months; urodynamic diagnosis of detrusor overactivity;\n             failed treatment with behavioral modification and anticholinergic medication\n\n        Exclusion Criteria:\n\n          -  active urinary tract infection; currently undergoing hemodialysis or has severe renal\n             impairment; bladder tumors; uncontrolled diabetes mellitus; post void residual\n             greater than 100ml; history of use of anticholinergic treatment within past 21 days;\n             history of urinary tract operation within 6 months prior to screening; heart failure;\n             uncontrolled hypertension; severe neurological disease; history of botox usage within\n             1 year"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects over 18 years of age will be screened for eligibility relative to patient\n        inclusion and exclusion criteria. If eligible to enroll, the nature and purpose of this\n        study will be explained to the subject with a witness present. The subject will review and\n        sign the written Informed Consent Form indicating informed consent and voluntary\n        participation in the study. A copy of the consent form including all risks and benefits to\n        research subjects is attached as a separate document."
            }
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850706", 
            "org_study_id": "11-060A"
        }, 
        "intervention_browse": {
            "mesh_term": "Mitogens"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "uNGF", 
            "urinary nerve growth factor", 
            "detrusor overactivity", 
            "InterStim", 
            "sacral neuromodulation", 
            "sacral nerve stimulation", 
            "quality of life", 
            "questionnaire", 
            "urodynamic detrusor overactivity", 
            "urodynamic DO"
        ], 
        "lastchanged_date": "January 21, 2014", 
        "location": {
            "contact": {
                "email": "npillalama@nshs.edu", 
                "last_name": "Nimmi Pillalamarri, MD", 
                "phone": "516-622-5114"
            }, 
            "facility": {
                "address": {
                    "city": "Manhasset", 
                    "country": "United States", 
                    "state": "New York"
                }, 
                "name": "North Shore University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Nirmala Pillalamarri, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dara Shalom, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Evaluation of Urinary Nerve Growth Factor as an Objective Tool to Assess Therapeutic Outcome in Patients With Detrusor Overactivity Undergoing Treatment With Sacral Neuromodulation", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "uNGF level in patients with urodynamically proven DO at baseline versus normal controls", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Change in uNGF levels in patients with urodynamic DO at baseline and 5 days, 1 month, 3 months, and 12 months after treatment with Interstim", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850706"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in quality of life questionnaire scores in patients with urodynamic DO at baseline and at 5 days, 1 month, 3 months, and 12 months after treatment with Interstim", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Correlation between uNGF levels and scores on validated quality of life questionnaires for urinary incontinence", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "North Shore Long Island Jewish Health System", 
        "sponsors": {
            "collaborator": {
                "agency": "Medtronics, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "North Shore Long Island Jewish Health System", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}